Schulte L, et al. - Among 5,093 patients treated for hepatocellular carcinoma (HCC) between 2000-2016 at three referral centers, researchers assessed if treatment with metformin for type 2 diabetes mellitus (T2DM) is correlated with prolonged overall survival in this retrospective multi-center study. Of the 5,093 HCC patients, 1,917 (37.6%) were diagnosed with T2DM, and 338 (17.6%) received metformin treatment. In patients with T2DM and HCC, treatment with metformin was related to improved survival, which was prolonged most significantly in patients treated with surgery.